🔎 Trials Near Me

Почетна › Рак на бели дробови со не-мали клетки › Пенсилванија › Pittsburgh

Клинички испитувања за Рак на бели дробови со не-мали клетки во Pittsburgh, PA

48 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Pittsburgh (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Се регрутираФаза 1/2
  • Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT06060613

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Се регрутираФаза 3
  • UPMC-Saint Margaret, Pittsburgh
  • UPMC-Mercy Hospital, Pittsburgh
  • UPMC Hillman Cancer Center, Pittsburgh
  • и уште 11
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Се регрутираФаза 2
  • UPMC-Saint Margaret, Pittsburgh
  • UPMC Hillman Cancer Center, Pittsburgh
  • UPMC-Shadyside Hospital, Pittsburgh
  • и уште 8
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Се регрутираФаза 1/2
  • University of Pittsburgh Medical Center, Pittsburgh
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Се регрутираФаза 1
  • Exelixis Clinical Site #32, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Се регрутираФаза 2
  • AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06780085

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Се регрутираФаза 3
  • UPMC Hillman Cancer Center, Pittsburgh
  • Bryn Mawr Hospital, Bryn Mawr · на 11 милји
  • UPMC Hillman Cancer Center - Monroeville, Monroeville · на 11 милји
  • и уште 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Се регрутираФаза 3
  • Local Institution - 0028, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07361510

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Се регрутираФаза 1
  • Research Site, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Се регрутираФаза 1
  • Research Site, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Се регрутираФаза 2
  • Bryn Mawr Hospital, Bryn Mawr · на 11 милји
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Се регрутираФаза 3
  • AHN Allegheny General Hospital, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06890598

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Се регрутираФаза 2
  • Research Site, Pittsburgh
Возраст од 18 до 95 · Сите полови · Ажурирано 23.9.2026 · NCT05061550

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Се регрутираФаза 2/3
  • West Penn Allegheny Health, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07100080

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Се регрутираФаза 1/2
  • Allegheny Health Network, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Се регрутираФаза 3
  • Clinical Study Site, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06767514

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Се регрутираФаза 1
  • UPMC, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Се регрутираФаза 2/3
  • Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT04613596

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Се регрутираФаза 1/2
  • Allegheny Singer, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06303505

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Се регрутираФаза 3
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Се регрутираФаза 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07012031

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Се регрутираФаза 1/2
  • University of Pittsburgh Medical Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT07070232

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Се регрутираФаза 1
  • University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 24.8.2026 · NCT06586515

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Се регрутираФаза 1
  • UPMC, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06774963

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Се регрутираФаза 1/2
  • Research Site, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT07115043

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Се регрутираФаза 1/2
  • Allegheny Health Network, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Се регрутираФаза 3
  • UPMC-Shadyside Hospital, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 14.7.2026 · NCT06686771

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Се регрутираФаза 1
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 9.7.2026 · NCT07315113

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Се регрутираФаза 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 30.6.2026 · NCT06162221

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Се регрутираФаза 2
  • Allegheny General Hospital, Natrona Heights · на 19 милји
Возраст од 18 до 70 · Сите полови · Ажурирано 26.6.2026 · NCT04614103

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Се регрутираФаза 3
  • AHN Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 25.6.2026 · NCT06216301

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Се регрутираФаза 1
  • University of Pittsburg Medical Center (UPCM), Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 11.6.2026 · NCT05283330

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Се регрутираФаза 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст од 18 до 70 · Сите полови · Ажурирано 11.6.2026 · NCT05361174

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Се регрутираФаза 1
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 8.6.2026 · NCT06026410

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Се регрутираФаза 1
  • UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT04777994

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Се регрутираФаза 2
  • UPMC-Saint Margaret, Pittsburgh
  • UPMC-Mercy Hospital, Pittsburgh
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
  • и уште 11
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Се регрутираФаза 3
  • Research Site, Pittsburgh
Возраст од 18 до 130 · Сите полови · Ажурирано 14.5.2026 · NCT06417814

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Се регрутираФаза 2/3
  • UPMC-Saint Margaret, Pittsburgh
  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
  • UPMC-Passavant Hospital, Pittsburgh
  • и уште 9
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Се регрутираФаза 3
  • Allegheny, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 16.4.2026 · NCT02468024

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Се регрутираФаза 2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 16.4.2026 · NCT07223424

A Study of VET3-TGI in Patients With Solid Tumors

Се регрутираФаза 1
  • UPMC- Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 7.4.2026 · NCT06444815

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Се регрутираФаза 2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 23.3.2026 · NCT05669846

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Се регрутираФаза 1
  • Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 6.3.2026 · NCT06171750

Impact of Circadian Rhythm on Immunotherapy

Се регрутираФаза 2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 9.12.2025 · NCT07224971

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Се регрутираФаза 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 21.10.2025 · NCT01720836

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Се регрутираФаза 2
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2025 · NCT06868485

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Се регрутираФаза 1
  • UPMC Hillman Cancer Center, Pittsburgh
Возраст 18 и постари · Сите полови · Ажурирано 5.3.2025 · NCT06069570

Испитувања за Рак на бели дробови со не-мали клетки во други градови

Други студии во Pittsburgh

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.